Biomea Fusion (NASDAQ:BMEA - Get Free Report) released its earnings results on Monday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.19, Zacks reports.
Biomea Fusion Price Performance
BMEA stock traded up $0.17 during midday trading on Friday, hitting $2.12. The stock had a trading volume of 735,838 shares, compared to its average volume of 911,745. Biomea Fusion has a 52-week low of $1.86 and a 52-week high of $13.66. The firm has a market cap of $79.65 million, a price-to-earnings ratio of -0.53 and a beta of -0.07. The business has a 50-day moving average of $3.10 and a two-hundred day moving average of $5.82.
Analysts Set New Price Targets
A number of research firms recently weighed in on BMEA. D. Boral Capital reaffirmed a "buy" rating and issued a $16.00 target price on shares of Biomea Fusion in a research report on Wednesday, March 19th. Barclays reduced their price objective on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating for the company in a report on Wednesday. Oppenheimer set a $10.00 price objective on shares of Biomea Fusion in a report on Monday, March 24th. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Biomea Fusion in a report on Monday, March 31st. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $23.91.
Check Out Our Latest Research Report on BMEA
Biomea Fusion Company Profile
(
Get Free Report)
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
Read More
Before you consider Biomea Fusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biomea Fusion wasn't on the list.
While Biomea Fusion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
